APA (7th ed.) Citation

Bauckneht, M., Capitanio, S., Donegani, M. I., Zanardi, E., Miceli, A., Murialdo, R., . . . Morbelli, S. (2020). Role of Baseline and Post-Therapy 18F-FDG PET in the Prognostic Stratification of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated with Radium-223. Cancers, 12(1), 31. https://doi.org/10.3390/cancers12010031

Chicago Style (17th ed.) Citation

Bauckneht, Matteo, et al. "Role of Baseline and Post-Therapy 18F-FDG PET in the Prognostic Stratification of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated with Radium-223." Cancers 12, no. 1 (2020): 31. https://doi.org/10.3390/cancers12010031.

MLA (9th ed.) Citation

Bauckneht, Matteo, et al. "Role of Baseline and Post-Therapy 18F-FDG PET in the Prognostic Stratification of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated with Radium-223." Cancers, vol. 12, no. 1, 2020, p. 31, https://doi.org/10.3390/cancers12010031.